Financials Neurogene Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
17.38 ^USD	+2.24%		-1.36%	-15.63%

02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI

Fiscal Period: December	2022	2023	2024	2025	2026	2027
Net sales ¹	-	-	0.925	-	-	-
Change	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-
Change	-	-	-	-	-	-
EBIT ¹	-	-55.58	-82.6	-103.4	-117.8	-132.3
Change	-	-	-48.62%	-25.19%	-13.88%	-12.31%
Interest Paid ¹	-	-	-0.012	-0.004	-0.004	-0.004
Earnings before Tax (EBT) ¹	-	-36.32	-75.14	-92.05	-105.4	-122.9
Change	-	-	-106.91%	-22.5%	-14.55%	-16.59%
Net income ¹	-55.19	-36.32	-75.14	-91.05	-113.5	-128.7
Change	-	34.2%	-106.91%	-21.16%	-24.69%	-13.34%
Announcement Date	08/11/23	18/03/24	24/03/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3
Net sales ¹	-	-	0.092	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	-14.73	-18.78	-20.13	-22.18	-21.51	-25.92	-26.08	-23.8	-28.21	-26.18	-26.76	-27.38	-28	-30	-31.5	-32.5
Change	-	-27.46%	-7.22%	-10.16%	3.01%	-20.49%	-0.63%	8.75%	-18.55%	7.22%	-2.24%	-2.29%	-2.28%	-7.14%	-5%	-3.17%
Charge d'intérêts ¹	-	-0.003	-0.004	-	-	-	-	-	-0.001	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	2.383	-16.92	-18.49	-20.22	-19.51	-22.65	-22.02	-20.95	-26.44	-23.42	-24.23	-25.07	-25.93	-28.47	-30.22	-31.48
Change	-	-810.07%	-9.28%	-9.33%	3.48%	-16.06%	2.79%	4.83%	-26.18%	11.41%	-3.45%	-3.47%	-3.44%	-9.79%	-6.14%	-4.18%
Net income ¹	2.383	-16.92	-18.49	-20.22	-19.51	-22.65	-22.02	-20.95	-25.44	-23.42	-24.23	-25.07	-25.93	-28.47	-30.22	-31.48
Change	-	-810.07%	-9.28%	-9.33%	3.48%	-16.06%	2.79%	4.83%	-21.44%	7.95%	-3.45%	-3.47%	-3.44%	-9.79%	-6.14%	-4.18%
Announcement Date	18/03/24	10/05/24	09/08/24	18/11/24	24/03/25	09/05/25	11/08/25	13/11/25	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2022	2023	2024	2025	2026	2027
Net Debt ¹	-	-197	-312	-235	-328	-
Change	-	-	-58.38%	24.78%	-39.57%	-
Announcement Date	08/11/23	18/03/24	24/03/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2023	2024	2025	2026	2027
CAPEX ¹	0.321	0.808	1.078	3	-
Change	-	151.71%	33.35%	178.42%	-100%
Free Cash Flow (FCF) ¹	-51.74	-71.41	-89.5	-103.5	-109.5
Change	-	-38.01%	-25.33%	-15.64%	-5.8%
Announcement Date	18/03/24	24/03/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-	-	-	-	-
EBIT Margin (%)	-	-	-8,930.27%	-	-	-
EBT Margin (%)	-	-	-8,123.68%	-	-	-
Net margin (%)	-	-	-8,123.68%	-	-	-
FCF margin (%)	-	-	-7,720.11%	-	-	-
FCF / Net Income (%)	-	142.48%	95.03%	98.3%	91.17%	85.1%
Profitability
ROA	-33.52%	-20.94%	-18.47%	-	-	-
ROE	-59.77%	-25.52%	-30.28%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	87.35%	-	-	-
CAPEX / EBITDA (%)	-	-	-	-	-	-
CAPEX / FCF (%)	-	-0.62%	-1.13%	-1.2%	-2.9%	-
Items per share
Cash flow per share ¹	-	-	-	-	-	-
Change	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-
Change	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-
Change	-	-	-	-	-	-
EPS ¹	-10.58	-7.798	-4.28	-4.279	-5.007	-5.56
Change	-	26.29%	45.12%	0.03%	-17.03%	-11.04%
Nbr of stocks (in thousands)	-	12,824	14,855	15,490	15,490	15,490
Announcement Date	08/11/23	18/03/24	24/03/25	-	-	-